Alkermes Plc
$ 37.00
-0.51%
19 May - close price
- Market Cap 6,198,673,000 USD
- Current Price $ 37.00
- High / Low $ 37.35 / 36.31
- Stock P/E 41.32
- Book Value 10.52
- EPS 0.90
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.09 %
- 52 Week High 39.56
- 52 Week Low 25.17
About
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Analyst Target Price
$45.44
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-25 | 2025-10-28 | 2025-07-29 | 2025-05-01 | 2025-02-12 | 2024-10-24 | 2024-07-24 | 2024-05-01 | 2024-02-15 | 2023-10-25 | 2023-07-26 |
| Reported EPS | 0.3812 | 0.29 | 0.6508 | 0.68 | 0.13 | 1.05 | 0.73 | 0.7 | 0.43 | 0.22 | 0.64 | 0.55 |
| Estimated EPS | -0.1762 | 0.41 | 0.38 | 0.38 | 0.05 | 0.76 | 0.71 | 0.7 | 0.58 | 0.51 | 0.44 | 0.46 |
| Surprise | 0.5574 | -0.12 | 0.2708 | 0.3 | 0.08 | 0.29 | 0.02 | 0 | -0.15 | -0.29 | 0.2 | 0.09 |
| Surprise Percentage | 316.3451% | -29.2683% | 71.2632% | 78.9474% | 160% | 38.1579% | 2.8169% | 0% | -25.8621% | -56.8627% | 45.4545% | 19.5652% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALKS
2026-05-12 22:39:58
Alkermes anticipates increased value from its acquisition of Avadel Pharmaceuticals following positive Phase III results for Lumryz in idiopathic hypersomnia (IH). However, due to a settlement with Jazz Pharmaceuticals, the launch of Lumryz is delayed until 2028. This development positions Alkermes to enter the commercial sleep market.
2026-05-12 18:10:21
Alkermes plc is scheduled to report its fourth quarter and year-end financial results on February 16, 2023. The company's recent activities include various SEC filings, insider transactions, and upcoming financial results announcements for different quarters, as tracked by Quantisnow. This report highlights recent analyst ratings and other corporate news surrounding Alkermes.
2026-05-12 11:09:58
Alkermes plc announced positive topline results from its REVITALYZ Phase 3 study, which evaluated LUMRYZ (sodium oxybate) extended-release for adults with idiopathic hypersomnia. The study met its primary endpoint, demonstrating robust efficacy for the treatment. This development marks a significant step for Alkermes in addressing neurological disorders.
2026-05-11 11:08:42
Alkermes (ALKS) reported strong first-quarter 2026 results, surpassing both earnings and revenue estimates. This positive financial performance led to a rise in the company's stock. The robust Q1 outcomes indicate a favorable outlook for the pharmaceutical company.
2026-04-22 17:09:55
This article provides an in-depth financial analysis of Alkermes Plc (ALKS), including its income statement, balance sheet, cash flow statement, and key financial ratios through FY2025. It highlights the company's strong cash generation despite a decline in sales, maintaining high gross margins and a robust balance sheet. The analysis also covers profitability, growth, leverage, liquidity, and returns, along with various financial health indicators like Altman Z-Score and Piotroski F-Score.
2026-04-22 16:09:50
Alkermes plc (Nasdaq: ALKS) announced that it will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. Interested parties can access the webcast on the Alkermes website.
